GRAL

4 - GRAIL, Inc. (0001699031) (Issuer)

3 - GRAIL, Inc. (0001699031) (Issuer)

Wolfe Research resumed coverage of GRAIL with a rating of Peer Perform

8-K - GRAIL, Inc. (0001699031) (Filer)

The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the New Cancers Detected by the Galleri Test Were in Stages I-IIIMENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Th

No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round  Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, RespectivelyGalleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of CareGRAIL to Host Analyst Call From 2026 ASCO Annual Meeting MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL),

MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 34,350 shares of GRAIL's common stock to 56 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

MENLO PARK, Calif., May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose missi

MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to de

SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

10-Q - GRAIL, Inc. (0001699031) (Filer)

8-K - GRAIL, Inc. (0001699031) (Filer)

Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access NationwideNew Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.

MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12 at 8:40 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to d

DEFA14A - GRAIL, Inc. (0001699031) (Filer)

DEF 14A - GRAIL, Inc. (0001699031) (Filer)

MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor

Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri® Clinical Development ProgramMENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Cl

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

Mizuho initiated coverage of GRAIL with a rating of Neutral and set a new price target of $58.00

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)